Clinical value of serum free ligh chain assay in Algerian newly diagnosed multiple myeloma undergoing high dose therapy

Abstract

A comparison is performed to correlate laboratory data according to current criteria IMWG published in the last quarter of 2014 to evaluate possible difficulties and potential solutions in diagnosis using these new criteria. Results: All patients were identified with and without BMPC infiltration >10% for cytology and /or demonstration of a bone or extramedullary plasmacytoma regardless of the rate of CM. All patients have met CRAB-classic symptomatic criteria according to 2003 criteria. 234 patients were analyzed. Median BMPC was 24.5 (range: 2.2 to 99%) Flow Chart (Figure 1) Analysis:Most patients were diagnosed by conventional Cytology (199/234) Of the 35 patients with BMPC<10%, 27 patients were diagnosed in the Department of Pathology (11 plasmacytomas and 16 by bone marrow biopsy) Only 5 of the 234 patients studied (2.1%) would not meet any of these criteria, even in the presence of clinical criteria CRAB-classics. Conclusions: The new basic criteria for pathological diagnosis of MM in need of treatment will probably not involve a substantial change in the diagnosis of new onset MM. 97.9% had one of the 2 pathological criteria “indispensable” (marrow infiltration and /or plasmacytoma) for the diagnosis of an MMS. Most patients can be diagnosed with a conventionally aspirated MO. Doubtful cases may benefit from completing the study with new biopsies directed by imaging tests (bone or extraosseous plasmacytomas) and /or BM biopsy for a better definition of the degree of plasma cell infiltration. In a small percentage of patients (around 2%) get not meet these essential criteria for the diagnosis of MM-no-quiescent. In these doubtful cases should be assessed clinically evident CRAB other “non-final” test (Flow Cytometry, FLC ...) and /or the repetition of imaging tests or directed biopsies. PO-079 Clinical value of serum free ligh chain assay in Algerian newly diagnosed multiple myeloma undergoing high dose therapy M. Yanis, M.C. Rahali, D. Bouchelouche, K. Bernine, N. Benfenatki, S.E. Belakehal, F.Z. Ardjoune, S. Chaib, R. Djidjik Department of Immunology, Central Hospital of Army, Algiers, Algeria; Department of Hematology, Central Hospital of Army, Algiers, Algeria; Department of Internal Medcin, Rouiba EPH, Algiers, Algeria; Department of Immunology, Beni-Messous Hospital, Algiers,